CN116870055A - 一种治疗带状疱疹的中药组合物及其制作方法 - Google Patents
一种治疗带状疱疹的中药组合物及其制作方法 Download PDFInfo
- Publication number
- CN116870055A CN116870055A CN202310820646.3A CN202310820646A CN116870055A CN 116870055 A CN116870055 A CN 116870055A CN 202310820646 A CN202310820646 A CN 202310820646A CN 116870055 A CN116870055 A CN 116870055A
- Authority
- CN
- China
- Prior art keywords
- parts
- herpes zoster
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 229910052957 realgar Inorganic materials 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 14
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940056582 human hair preparation Drugs 0.000 claims abstract description 14
- 241000258920 Chilopoda Species 0.000 claims abstract description 9
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940037003 alum Drugs 0.000 claims abstract description 8
- 229940116229 borneol Drugs 0.000 claims abstract description 8
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 8
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 241000131808 Scolopendra Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 240000004980 Rheum officinale Species 0.000 claims description 5
- 235000008081 Rheum officinale Nutrition 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 229960004150 aciclovir Drugs 0.000 claims description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000002193 Pain Diseases 0.000 abstract description 13
- 239000003053 toxin Substances 0.000 abstract description 7
- 231100000765 toxin Toxicity 0.000 abstract description 7
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 208000004296 neuralgia Diseases 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 241000700605 Viruses Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种治疗带状疱疹的中药组合物及其制作方法，原料以重量份数计包括如下成分：血余炭50‑100份，青黛10‑30份，雄黄5‑20份，枯矾10‑20份，蜈蚣5‑10份，冰片5‑10份。本发明具有止痛、消疹、拔毒和修复的作用；修复后不留疤痕。本发明组方巧妙，配伍合理；药味少，具有副作用少，治疗效果好的效果。本发明还可以有效治疗带状疱疹后遗症导致的神经痛。
Description
技术领域
本发明属于中药技术领域，具体涉及一种治疗带状疱疹的中药组合物及其制作方法。
背景技术
带状疱疹患者近年来有明显增加的趋势，患病率和发病率急骤攀升，而且好多病人由于失治误治，而使本病迁延难愈，形成带状疱疹后遗症神经痛，其痛彻心，经年累月，痛苦不堪。
带状疮疹是由水痘-带状疱疹病毒感染引起的病毒性皮肤病，一般是在小儿时感染了水痘-带状疱疹病毒，由于没有彻底治愈，致使带状疱疹病毒长期潜伏于脊髓神经后跟神经节的神经元内，当患者免疫力下降或劳累，体弱，心情煎熬，或患有其他疾病免疫功能被破坏时，病毒就开始复制，并沿神经纤维移至皮肤。由于带状疱疹病毒具有嗜神经性的特点，致使受侵犯的神经和皮肤产生强烈的疼痛及疱疹性炎症。
西医临床分型大致为：无疱疹型、大疱疹型，出血型和坏疽型带状疱疹，症状由轻至重，疼痛逐渐剧烈。中医认为带状疱疹是由带状疱疹病毒感染引起的一种常见皮肤病，本病多见于中、老年人，尤其以老年人居多，症状普通较重，疼痛剧烈。带状疱疹中医称之为：缠腰火龙、缠腰火丹、缠腰瘤、蛇患疮等；多因情志不遂，饮食失调，以致脾失健运，湿浊内停，郁而化热，湿热郁结，兼感毒邪而发。
本病的西医治疗用药一般都用：阿昔洛韦，伐昔洛韦，颅痛定等等，效果都很差。尤其是火疗，艾炙、电烤；刺血拔罐等方法，要么火毒入里加重病情，要么虽然有拔毒之效，但是却破坏了原来的皮肤组织和末梢神经的生理结构，更是雪上加霜，致使病人的带状疱疹进入疼痛无休止的后遗症期。
中医将带状疱疹分为肝经郁热，脾虚湿蕴，气滞血瘀等症，用汤药口服治疗，效果亦显著。
发明内容
本发明为了克服现有问题，提供一种治疗带状疱疹的中药组合物及其制作方法；本发明的目的在于提供一种具有止痛、消疹，拔毒，修复作用的带状疱疹治疗剂。
为了达到上述目的，本发明的技术方案如下：
一种治疗带状疱疹的中药组合物，原料以重量份数计包括如下成分：
血余炭50-100份，青黛10-30份，雄黄5-20份，枯矾10-20份，蜈蚣5-10份，冰片5-10份。
作为改进，所述雄黄替换为大黄。
本发明的制作方法，包括如下步骤：
S1.将血余炭、青黛、雄黄或大黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，按照1：3的比例加入阿昔洛韦软膏和匀，调成糊状。
作为改进，所述S3步骤药物制作成水、酒精、米醋的浸出液。
血余炭：为人发洗净后的加工品，性平，味苦，有止血散瘀，补阴利尿之功。本品既有收涩止血作用，又有能散瘀血，故不致留瘀为患，对出血型和坏疽型重症带状疱疹尤为合拍，《医学衷中参西录》云：“血余能化瘀血，生新血，使血管流通最有斯效。”中医认为带状疮疹为火毒所发，而血余炭又有补阴清热之功，故血余炭具止血、散瘀、补阴三功，故为君药。
青黛：其性咸寒。具有清热解毒，凉血散肿之效，用于热毒发斑及血热妄行，热毒痈疮等恰中病机，故而为臣。
雄黄：为含砷的结晶矿石(二硫化二砷AS2S2)，主要功效及作用是解毒杀虫，燥湿祛痰等，临床常用于治疗痈肿疔疮，蛇虫咬伤等症。《本草纲目》记载：雄黄温燥有毒，可攻毒疗疮，为“治疮杀毒要药”。唯本品切忌火煅，煅烧后即分解氧化为三氧化二砷(AS2O3)，有剧毒。雄黄能从皮肤吸收，故局部外用亦不能大面积涂搽及长期单独持续使用本品。
为用药安全第一的原则，本药方宜可不用雄黄，用大黄等量代替，效果影响不是很大。
枯矾：性味酸、涩、寒，有收湿敛疮，止血化腐之效，针对于大疱疹型及出血型带状疱疹甚为恰当。
蜈蚣：辛、温、有毒。其功效为：息风止痉，解毒散结，通络止痛。本品用于疮疡肿毒，瘰疬溃烂等症，具有较强的解毒散结作用和良好的解痉、通络、止痛的功效，故用之可达到迅速解毒，止痛之效。
冰片：辛、苦、微寒，内服开窍醒神，外用清热止痛，防腐止痒。《本草纲目》云：“通诸窍，散郁火”。“芳香之气，能辟一切邪恶”。
本发明的优点在于：
1.本发明由血余炭、青黛、蜈蚣等组成，具有止痛、消疹、拔毒和修复的作用；修复后不留疤痕。
2.本发明组方巧妙，配伍合理；药味少，具有副作用少，治疗效果好的效果。
3.本发明还可以有效治疗带状疱疹后遗症导致的神经痛。
具体实施方式
下面通过具体实施例对本发明进行详细和具体的介绍，以使更好的理解本发明，但是下述实施例并不限定本发明的保护范围。
实施例1
本实施例公开了一种治疗带状疱疹的中药组合物，包括：
血余炭50g，青黛20g，雄黄5g，枯矾10g，蜈蚣5g，冰片5g。
本实施例的制作方法包括如下步骤：
S1.将血余炭、青黛、雄黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，按照1：3的比例加入阿昔洛韦软膏和匀，调成糊状。
本实施例的使用方法为：将调和好的药膏涂覆在患处，每天涂覆两次，8-12小时一次，涂覆后，使用纱布覆盖，以免粘衣。
本实施例在带状疱疹初期，即急性发作期1-10天内，有效率为100％，治愈率为100％。用药1-2天后，临床症状明显改善；用药3-5天，疼痛消失，水泡结痂脱落；用药10天左右治愈，皮肤不留痕迹。
实施例2
本实施例公开了一种治疗带状疱疹的中药组合物，包括：
血余炭100g，青黛30g，雄黄20g，枯矾20g，蜈蚣10g，冰片10g。
本实施例的制作方法包括如下步骤：
S1.将血余炭、青黛、雄黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，制作成水的浸出液。
本实施例的使用方法为：将浸出液涂覆在患处，每天涂覆两次，8-12小时一次，涂覆后，使用纱布覆盖，以免粘衣。
实施例3
本实施例公开了一种治疗带状疱疹的中药组合物，包括：
血余炭75g，青黛25g，大黄15g，枯矾15g，蜈蚣8g，冰片8g。
本实施例的制作方法包括如下步骤：
S1.将血余炭、青黛、大黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，制作成酒精的浸出液。
本实施例的使用方法为：将浸出液涂覆在患处，每天涂覆两次，8-12小时一次，涂覆后，使用纱布覆盖，以免粘衣。
实施例4
本实施例公开了一种治疗带状疱疹的中药组合物，包括：
血余炭60g，青黛15g，大黄18g，枯矾12g，蜈蚣6g，冰片6g。
本实施例的制作方法包括如下步骤：
S1.将血余炭、青黛、大黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，制作成米醋的浸出液。
本实施例的使用方法为：将浸出液涂覆在患处，每天涂覆两次，8-12小时一次，涂覆后，使用纱布覆盖，以免粘衣。
以上对本发明的具体实施例进行了详细描述，但其只是作为范例，本发明并不等同于以上描述的具体实施例。对于本领域技术人员而言，任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此，不脱离本发明的精神和范围下所做的均等变换和修改，都应涵盖在本发明的范围内。
Claims (4)
1.一种治疗带状疱疹的中药组合物，其特征在于，原料以重量份数计包括如下成分：
血余炭50-100份，青黛10-30份，雄黄5-20份，枯矾10-20份，蜈蚣5-10份，冰片5-10份。
2.根据权利要求1所述的一种治疗带状疱疹的中药组合物，其特征在于，所述雄黄替换为大黄。
3.一种基于权利要求1所述的治疗带状疱疹的中药组合物的制作方法，其特征在于，包括如下步骤：
S1.将血余炭、青黛、雄黄或大黄，枯矾、蜈蚣低温干燥后，加入冰片粉碎；
S2.过80目筛后，混合均匀；
S3.将S2步骤所得混合后的药物粉末，按照1：3的比例加入阿昔洛韦软膏和匀，调成糊状。
4.根据权利要求1所述的一种治疗带状疱疹的中药组合物的制作方法，其特征在于，所述S3步骤药物制作成水、酒精、米醋的浸出液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310820646.3A CN116870055A (zh) | 2023-07-06 | 2023-07-06 | 一种治疗带状疱疹的中药组合物及其制作方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310820646.3A CN116870055A (zh) | 2023-07-06 | 2023-07-06 | 一种治疗带状疱疹的中药组合物及其制作方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116870055A true CN116870055A (zh) | 2023-10-13 |
Family
ID=88263669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310820646.3A Pending CN116870055A (zh) | 2023-07-06 | 2023-07-06 | 一种治疗带状疱疹的中药组合物及其制作方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870055A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612240A (zh) * | 2009-07-27 | 2009-12-30 | 郭静 | 一种治疗带状疱疹的外用药 |
| CN105520973A (zh) * | 2016-01-28 | 2016-04-27 | 胶州市人民中医医院 | 一种治疗带状孢疹的中药组合物及制备方法 |
| CN107737163A (zh) * | 2017-12-05 | 2018-02-27 | 湖北黄仙洞葛业食品有限公司 | 一种中药擦拭剂及其制备方法 |
-
2023
- 2023-07-06 CN CN202310820646.3A patent/CN116870055A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612240A (zh) * | 2009-07-27 | 2009-12-30 | 郭静 | 一种治疗带状疱疹的外用药 |
| CN105520973A (zh) * | 2016-01-28 | 2016-04-27 | 胶州市人民中医医院 | 一种治疗带状孢疹的中药组合物及制备方法 |
| CN107737163A (zh) * | 2017-12-05 | 2018-02-27 | 湖北黄仙洞葛业食品有限公司 | 一种中药擦拭剂及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 邢惠芝: "乌黛膏联合阿昔洛韦治疗带状疱疹48例疗效观察", 中医药学报, vol. 37, no. 05, 20 October 2009 (2009-10-20), pages 87 - 89 * |
| 陈斌: "带状疱疹验方", 贵阳中医学院学报, no. 03, 31 December 1991 (1991-12-31), pages 53 * |
| 马璋玲: "侯平玺教授治疗带状疱疹经验举隅", 中医药研究, vol. 18, no. 02, 20 April 2002 (2002-04-20), pages 32 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100394954C (zh) | 一种外敷红膏药 | |
| CN102526662B (zh) | 用于人体穴位敷贴的治疗哮喘的中药磁疗外贴膏 | |
| CN108310320A (zh) | 一种治疗痛风的外用药及其制备方法 | |
| CN101143171B (zh) | 一种中药药物、其制备方法及其应用 | |
| CN103845578B (zh) | 治疗烧烫伤、褥疮、带状疱疹外用酊剂及制备方法 | |
| WO2021062888A1 (zh) | 一种具有促进骨关节健康作用的复方组合物及其应用 | |
| CN110339325A (zh) | 一种治疗痹症的外用药酒及其制备方法 | |
| CN109758514A (zh) | 一种用于止痛的中药组合物及其制备方法 | |
| CN116870055A (zh) | 一种治疗带状疱疹的中药组合物及其制作方法 | |
| CN105943778A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法 | |
| CN109010549A (zh) | 接骨祛风活血止痛膏及其制备方法 | |
| CN113332365B (zh) | 一种复方紫草膏及其制备方法 | |
| CN110420252B (zh) | 一种用于治疗病毒性流行性腮腺炎的中药组合物、药物及其制备方法 | |
| CN108066466A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法与应用 | |
| CN107050302A (zh) | 治疗烧烫伤的外用中药 | |
| CN103394009B (zh) | 一种治疗外伤和糠尿病足溃疡的中药及制备方法 | |
| CN1170570C (zh) | 治疗烧伤、烫伤拔毒软膏及其制备工艺 | |
| CN115120637B (zh) | 一种抗菌抗病毒药液及其制备方法 | |
| CN102657824A (zh) | 一种治疗骨折的药物 | |
| CN106728618A (zh) | 一种治疗重症急性胰腺炎的中药 | |
| CN108066738B (zh) | 一种治疗痛风性关节炎的药膏及其制备方法 | |
| CN101983681A (zh) | 一种治疗白带异常的药剂 | |
| CN116898932A (zh) | 一种外用创伤药及制备方法 | |
| CN105213732A (zh) | 一种褥疮膏及其制备方法 | |
| CN105381117A (zh) | 一种治疗风痹的中药贴膏及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |